Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL18174171 | 0.98 | ALDH1A1 (0.45) | ALDH1A1LMNACYP3A4TDP1PDGFRB | |
| SCHEMBL27649957 | 0.86 | ALDH1A1 (0.47) | ALDH1A1LMNACYP3A4TDP1NPC1 | |
| SCHEMBL11066620 | 0.84 | ALDH1A1 (0.67) | ALDH1A1LMNACYP3A4TDP1PDGFRB | |
| SCHEMBL525661 | 0.84 | PDGFRB (0.47) | ALDH1A1TDP1PDGFRBFGFR1PDGFRA | |
| SCHEMBL11526281 | 0.83 | POLB (0.53) | ALDH1A1LMNATDP1NPC1POLB | |
| SCHEMBL11510888 | 0.83 | ALDH1A1 (0.59) | ALDH1A1LMNATDP1POLBKDM4E | |
| SCHEMBL29607722 | 0.83 | ALDH1A1 (0.45) | ALDH1A1LMNANPC1POLBKDM4E | |
| SCHEMBL3722699 | 0.83 | ALDH1A1 (0.45) | ALDH1A1LMNANPC1POLBKDM4E | |
| SCHEMBL11430270 | 0.83 | ALDH1A1 (0.54) | ALDH1A1LMNACYP3A4NPC1POLB | |
| SCHEMBL2395918 | 0.83 | ALDH1A1 (0.56) | ALDH1A1LMNATDP1PDGFRBFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482376-B2 | Conjugated complement cascade inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-7482376-B2 | Conjugated complement cascade inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| CN-100412073-C | Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | DIMENSIONAL PHARM INC (US) | 2008-08-20 | — | — | CN | disclosed |
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7109354-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1644046-A2 | CONJUGATED COMPLEMENT CASCADE INHIBITORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1549632-A4 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | DIMENSIONAL PHARM INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | disclosed |
| CN-1665800-A | Novel thiophenecarboxamidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | DIMENSIONAL PHARM INC (US) | 2005-09-07 | — | — | CN | disclosed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2005002627-A2 | CONJUGATED COMPLEMENT CASCADE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004031-A1 | Conjugated complement cascade inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | ALDH1A1 3674/4885LMNA 4410/4885CYP3A4 1530/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | ALDH1A1 2779/4885LMNA 4320/4885CYP3A4 1112/4885 |
| US-20050004031-A1 | Conjugated complement cascade inhibitors | C9, CFH, CFB | ALDH1A1 3147/4885LMNA 2162/4885CYP3A4 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.